Pharmaceutical and Life Sciences Real World Evidence Global Market Report 2026

The pharmaceutical and life sciences real world evidence market size has grown rapidly in recent years. It will grow from $3.2 billion in 2025 to $3.57 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing adoption of electronic health records, growing focus on drug safety monitoring, expansion of patient registries, rising demand for evidence-based decision making, growth of pharmaceutical R&D investments.

The pharmaceutical and life sciences real world evidence market size is expected to see rapid growth in the next few years. It will grow to $5.6 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to integration of ai-driven analytics, expansion of rwe platforms and dashboards, adoption of predictive modeling tools, increasing collaboration between payers and pharma, growth of real-world evidence in personalized medicine. Major trends in the forecast period include integration of real-world data sources, predictive modeling for drug outcomes, patient-centric evidence generation, regulatory compliance optimization, advanced analytics for market access.

The growing demand for personalized medicine is expected to drive the growth of the pharmaceutical and life sciences real-world evidence market going forward. Personalized medicine is a healthcare approach that tailors therapies based on an individual’s unique biological and personal characteristics. Its adoption is increasing due to advances in genomic technologies, which allow healthcare providers to analyze genetic information rapidly and accurately, enabling more targeted and effective treatments. Real-world evidence in pharmaceutical and life sciences supports personalized medicine by analyzing actual patient data to identify the most effective and safe treatments for specific patient subgroups. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. These newly approved treatments include seven cancer drugs and three for other conditions. Consequently, the growing demand for personalized medicine is fueling the growth of the pharmaceutical and life sciences real-world evidence market.

Leading companies operating in the pharmaceutical and life sciences real-world evidence market are concentrating on developing integrated data-driven platforms to enhance clinical trial efficiency, improve patient engagement, and support regulatory and health economics submissions. Integrated data-driven platforms combine diverse real-world data sources, including patient-reported outcomes and wearable device data, into structured modules that streamline recruitment, screening, enrollment, and ongoing patient interaction. For example, in September 2023, Maxis Clinical Sciences, a US-based boutique consulting firm, introduced a comprehensive real-world evidence solution designed to support patient-focused clinical research and drug development. The platform integrates multiple data streams into pre-configured operational modules, enabling faster trial execution while facilitating regulatory approvals, health economics and outcomes research (HEOR), and drug repurposing strategies.

In July 2025, Datavant Inc., a US-based healthcare data connectivity and analytics company, acquired Aetion Inc. for an undisclosed sum. This acquisition enables Datavant Inc. to strengthen its real-world evidence and analytics platform by incorporating Aetion Inc.’s advanced real-world data analysis capabilities, facilitating more comprehensive healthcare insights and streamlined data-driven research. Aetion Inc. is a US-based health technology company focused on real-world evidence generation and analytics solutions for healthcare and life sciences.

Major companies operating in the pharmaceutical and life sciences real world evidence market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc., ICON plc, Parexel International Corporation, Cegedim SA, Veradigm Inc., Tempus AI Inc., Saama Technologies LLC, Komodo Health Inc., Owkin Inc., Trinity Life Sciences LLC, TriNetX LLC, OM1 Inc., HealthVerity Inc., Claritas Rx Inc., PurpleLab Inc., Atropos Health PBC, EvidentIQ Group GmbH, CuriMeta Inc., Medaffcon Oy, and Mahalo Health Inc.

North America was the largest region in the pharmaceutical and life sciences real world evidence market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical and life sciences real world evidence market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical and life sciences real world evidence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmaceutical and life sciences real-world evidence market consists of revenues earned by entities by providing services such as observational study design, data collection and management, and real-world data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmaceutical and life sciences real-world evidence (RWE) refers to clinical insights on the safety, efficacy, and outcomes of drugs or therapies obtained from data collected outside traditional clinical trials. This information comes from sources such as electronic health records, insurance claims, patient registries, and routine clinical practice, supporting evidence-based decisions in drug development and patient care.

The essential components of pharmaceutical and life sciences real-world evidence include services, software, and data sets. Services refer to offerings that assist in designing, collecting, analyzing, and interpreting real-world evidence to support clinical, regulatory, and commercial decision-making. They are categorized into descriptive studies, analytical studies, and patient-reported outcomes and leverage real-world data sources such as medical claims, clinical trials, clinical settings, patient-powered data, and other sources. Applications include drug discovery and development support, regulatory submission and label expansion, market access and reimbursement strategy, drug safety and pharmacovigilance monitoring, treatment decision support and clinical optimization, and comparative effectiveness and outcomes research, serving pharmaceutical and biopharmaceutical companies, healthcare payers and providers, medical technology firms, regulatory and health technology assessment bodies, contract research organizations, and academic research institutions.

Tariffs have affected the pharmaceutical and life sciences RWE market by raising costs for importing advanced software, data management tools, and analytics platforms. Segments such as software and services are particularly impacted in regions like North America and Europe that rely on imported RWE solutions. While tariffs have temporarily slowed adoption, they are encouraging local development of data analytics platforms and services, fostering innovation, cost optimization, and resilience in the market.

The pharmaceutical and life sciences real world evidence market research report is one of a series of new reports that provides pharmaceutical and life sciences real world evidence market statistics, including pharmaceutical and life sciences real world evidence industry global market size, regional shares, competitors with a pharmaceutical and life sciences real world evidence market share, detailed pharmaceutical and life sciences real world evidence market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical and life sciences real world evidence industry. This pharmaceutical and life sciences real world evidence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.